Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

FGFR-driven lung cancer: Dissecting resistance and exploring therapeutic avenues.

Critical reviews in oncology/hematology - 1 May 2026

Zhang Pengfei, Mei Wuxuan, Yao Yueru, Zeng Changchun, Li Wei

Abstract excerpt

Fibroblast growth factor receptors (FGFRs) are significant oncogenic contributors in lung cancer. The clinical development of FGFR-directed agents represents a promising advancement in precision oncology. However, their efficacy is substantially limited by the emergence of diverse resistance mechanisms. This review summarizes FGFR biology, genomic alterations, and signaling pathways in tumorigenesis. Nonselective...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Molecular Targeted Therapy

Share to Protein Kinase Inhibitors

Share to Receptors, Fibroblast Growth Factor

Share to Signal Transduction

Share to Tumor Microenvironment

Source

Identifiers

PMID: 41679523
DOI: 10.1016/j.critrevonc.2026.105205

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

FGFR-driven lung cancer: Dissecting resistance and exploring therapeutic avenues.PMID 41679523Read ↗

Targeting the Fibroblast Growth Factor Receptor (FGFR) Family in Lung Cancer.Semantic proximity Read ↗

Clinical advances and challenges in targeting FGF/FGFR signaling in lung cancerSemantic proximity Read ↗

RAS-MAPK Reactivation Facilitates Acquired Resistance in FGFR1-Amplified Lung Cancer and Underlies a Rationale for Upfront FGFR-MEK Blockade.Semantic proximity Read ↗

FGFR as potential target in the treatment of squamous non small cell lung cancer.Semantic proximity Read ↗

Role of FGF Receptors as an Emerging Therapeutic Target in Lung Squamous Cell CarcinomaSemantic proximity Read ↗

FGFR-TKI resistance in cancer: current status and perspectives.Semantic proximity Read ↗

Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapySemantic proximity Read ↗

FGFR a promising druggable target in cancer: Molecular biology and new drugs.Semantic proximity Read ↗

Kinase domain activation of FGFR2 yields high-grade lung adenocarcinoma sensitive to a Pan-FGFR inhibitor in a mouse model of NSCLC.Semantic proximity Read ↗

Personalized therapy for lung cancer: striking a moving target.Semantic proximity Read ↗

Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma.Semantic proximity Read ↗

Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.